{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:09:35Z","timestamp":1794604175678,"version":"4.9.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1136\/ard-2023-224999","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T18:20:13Z","timestamp":1699554013000},"page":"407-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Obinutuzumab in patients with Sjogren\u2019s disease immunised against rituximab"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1256-1748","authenticated-orcid":false,"given":"Mathilde","family":"Pezot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-0733","authenticated-orcid":false,"given":"Ga\u00e9tane","family":"Nocturne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakiba","family":"Belkhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Pavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-1856","authenticated-orcid":false,"given":"Rapha\u00e8le","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-2269","authenticated-orcid":false,"given":"Samuel","family":"Bitoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224999_bib1","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/annrheumdis-2019-215200","article-title":"Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus","volume":"78","author":"Wincup","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224999_bib2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/rheumatology\/kez430","article-title":"Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: Ofatumumab as alternative therapy","volume":"59","author":"Combier","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224999_bib3","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224999_bib4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2021-221756","article-title":"Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series","volume":"81","author":"Kvacskay","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224999_bib5","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224999_bib6","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1093\/rheumatology\/keac150","article-title":"Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab","volume":"61","author":"Arnold","year":"2022","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:09:54Z","timestamp":1736057394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724003716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0003496724003716"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224999","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obinutuzumab in patients with Sjogren\u2019s disease immunised against rituximab","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}